PARIS — Long-term 7-year follow-up data from the Portal extension trial support the port delivery system as an effective strategy to maintain long-term visual outcomes with reduced treatment burden.
At the Euretina congress, Arshad M. Khanani, MD, MA, FASRS, said that the trial was the longest prospective study of patients with wet age-related macular degeneration ever performed.
“We are all aware that patients in the real world lose vision due to under treatment with injections due to treatment burden,” Khanani told Healio. “This data from the port delivery system shows much improved long-term